Document:

Series A Preferred Stock Purchase Agreement

 Exhibit 10.1 
 CALANDO PHARMACEUTICALS INC. 
 SERIES A PREFERRED STOCK PURCHASE AGREEMENT 
 March 31, 2006 

 TABLE OF CONTENTS 
  

							
	 	  	 	  	 	  	Page
	 1.
	  	PURCHASE AND SALE OF STOCK	  	1
		  	1.1	  	Sale and Issuance of Series A Preferred Stock	  	1
		  	1.2	  	Closing	  	1
			
	 2.
	  	REPRESENTATIONS AND WARRANTIES OF THE COMPANY	  	1
		  	2.1	  	Organization, Good Standing and Qualification	  	1
		  	2.2	  	Capitalization and Voting Rights	  	2
		  	2.3	  	Subsidiaries	  	3
		  	2.4	  	Authorization	  	3
		  	2.5	  	Valid Issuance of Preferred and Common Stock	  	3
		  	2.6	  	Governmental Consents	  	3
		  	2.7	  	Offering	  	4
		  	2.8	  	Litigation	  	4
		  	2.9	  	Proprietary Information Agreements	  	4
		  	2.10	  	Patents and Trademarks	  	4
		  	2.11	  	Compliance with Other Instruments	  	4
		  	2.12	  	Agreements; Action	  	5
		  	2.13	  	Related-Party Transactions	  	5
		  	2.14	  	No Undisclosed Liabilities	  	5
		  	2.15	  	Permits	  	6
		  	2.16	  	Environmental and Safety Laws	  	6
		  	2.17	  	Disclosure	  	6
		  	2.18	  	Registration Rights	  	6
		  	2.19	  	Corporate Documents; Minute Books	  	6
		  	2.20	  	Title to Property and Assets	  	6
		  	2.21	  	Labor Agreements and Actions	  	7
			
	 3.
	  	REPRESENTATIONS AND WARRANTIES OF INVESTOR	  	7
		  	3.1	  	Authorization	  	7
		  	3.2	  	Purchase Entirely for Own Account	  	7
		  	3.3	  	Disclosure of Information	  	7
		  	3.4	  	Investment Experience	  	8
		  	3.5	  	Accredited Investor	  	8
		  	3.6	  	Restricted Securities	  	8
		  	3.7	  	Legends	  	8
			
	 4.
	  	CONDITIONS OF INVESTOR’S OBLIGATIONS AT CLOSING	  	8
		  	4.1	  	Representations and Warranties	  	8
		  	4.2	  	Performance	  	8
		  	4.3	  	Compliance Certificate	  	9

  

 i. 

							
		  	4.4	  	Qualifications	  	9
		  	4.5	  	Proceedings and Documents	  	9
		  	4.6	  	Restated Certificate	  	9
		  	4.7	  	Secretary’s Certificate	  	9
		  	4.8	  	Investors’ Rights Agreement	  	9
		  	4.9	  	Co-Sale Agreement	  	9
		  	4.10	  	Voting Agreement	  	9
		  	4.11	  	Agreement to Provide Additional Capital	  	9
		  	4.12	  	Common Stock Transfer Agreement – Form A	  	9
		  	4.13	  	Common Stock Transfer Agreement – Form B	  	10
			
	 5.
	  	CONDITIONS OF THE COMPANY’S OBLIGATIONS	  	10
		  	5.1	  	Representations and Warranties	  	10
		  	5.2	  	Payment of Purchase Price	  	10
		  	5.3	  	Qualifications	  	10
		  	5.4	  	Investors’ Rights Agreement	  	10
		  	5.5	  	Co-Sale Agreements	  	10
		  	5.6	  	Voting Agreements	  	10
		  	5.7	  	Additional Capital Agreement	  	10
		  	5.8	  	Form A Transfer Agreement	  	10
		  	5.9	  	Form B Transfer Agreement	  	10
			
	 6.
	  	MISCELLANEOUS	  	10
		  	6.1	  	Survival	  	10
		  	6.2	  	Successors and Assigns	  	11
		  	6.3	  	Governing Law	  	11
		  	6.4	  	Titles and Subtitles	  	11
		  	6.5	  	Notices	  	11
		  	6.6	  	Finder’s Fee	  	11
		  	6.7	  	Amendments and Waivers	  	11
		  	6.8	  	Severability	  	11
		  	6.9	  	Aggregation of Stock	  	12
		  	6.10	  	Entire Agreement	  	12
		  	6.11	  	Counterparts	  	12

  

			
	 SCHEDULE A
	  	Schedule of Exceptions
		
	 EXHIBIT A
	  	Amended and Restated Certificate of Incorporation
		
	 EXHIBIT B
	  	List of Stockholders
		
	 EXHIBIT C
	  	Amended and Restated Investors’ Rights Agreement
		
	 EXHIBIT D
	  	Right of First Refusal and Co-Sale Agreement
		
	 EXHIBIT E
	  	Amended and Restated Voting Agreement
		
	 EXHIBIT F
	  	Agreement to Provide Additional Capital
		
	 EXHIBIT G
	  	Common Stock Transfer Agreement – Form A
		
	 EXHIBIT H
	  	Common Stock Transfer Agreement – Form B

  

 ii. 

 SERIES A PREFERRED STOCK PURCHASE AGREEMENT 
 THIS SERIES A PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”) is made on the 31st day of March, 2006, among Calando
Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Arrowhead Research Corporation, a Delaware corporation (“Investor”). 
 THE PARTIES HEREBY AGREE AS FOLLOWS: 
 1.
Purchase and Sale of Stock. 
 1.1 Sale and Issuance of Series A Preferred Stock. 
 (a) The Company shall adopt and file with the Secretary of State of the State of Delaware on or before the Closing (as defined below) the
Amended and Restated Certificate of Incorporation in the form attached hereto as Exhibit A (the “Restated Certificate”). 
 (b) Subject to the terms and conditions of this Agreement, Investor agrees to purchase at the Closing (as defined herein) and the Company agrees to sell and issue to Investor at the Closing, Five Million
(5,000,000) shares of the Company’s Series A Preferred Stock for a purchase price of $0.60 per share. 
 1.2
Closing. The purchase and sale of the Series A Preferred Stock hereunder shall take place at the offices of Dorsey & Whitney LLP, 38 Technology Drive, Irvine, California, 92618, at 1:00 P.M. on March 31, 2006, or at such other
time and place as the Company and Investor mutually agree upon orally or in writing (which time and place are designated as the “Closing”). At the Closing, the Company shall deliver to Investor a certificate representing the
Series A Preferred Stock that such Investor is purchasing against payment of the purchase price therefor by wire transfer. 
 2.
Representations and Warranties of the Company. The Company hereby represents and warrants to Investor that, except as set forth on the Schedule of Exceptions (the “Schedule of Exceptions”) furnished to Investor prior
to execution hereof and attached hereto as Schedule A, which exceptions shall be deemed to be representations and warranties as if made hereunder: 
 2.1 Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Company is duly qualified to
transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a material adverse effect on its business or properties. 
  

 1 

 2.2 Capitalization and Voting Rights 
 (a) Authorized Stock. Immediately prior to the Closing, the authorized capital of the Company consists, or will consist, of:

 (i) Preferred Stock. Five Million (5,000,000) shares of Preferred Stock, par value $0.0001 (the
“Preferred Stock”), all of which have been designated Series A Preferred Stock (the “Series A Preferred Stock”) which will be sold in the Closing pursuant to this Agreement. The rights, privileges and
preferences of the Series A Preferred Stock will be as stated in the Company’s Restated Certificate. 
 (ii) Common
Stock. Eighteen Million (18,000,000) shares of Common Stock, par value $0.0001 (“Common Stock”), of which Seven Million Four Hundred Forty Thousand (7,440,000) shares are issued and outstanding. 
 (b) Security Holders. The outstanding shares of Common Stock are owned by the stockholders and in the numbers specified in
Exhibit B hereto. 
 (c) Valid Issuance. The outstanding shares of Common Stock are all duly and validly
authorized and issued, fully paid and nonassessable, and were issued in compliance with all applicable state and federal laws concerning the issuance of securities. 
 (d) Rights to Acquire. Except for (i) the conversion privileges of the Series A Preferred Stock to be issued under this
Agreement, (ii) the rights provided in the Investors’ Rights Agreement to be entered into in connection with the Closing, (iii) currently outstanding warrants to purchase an aggregate of Two Million Seven Hundred Thousand
(2,700,000) shares of Common Stock and (iv) currently outstanding options to purchase One Hundred Thirty Seven Thousand Five Hundred (137,500) shares of Common Stock granted to employees, consultants and/or directors pursuant to the
Company’s 2005 Stock Option/Stock Issuance Plan (the “Option Plan”), there are not outstanding any options, warrants, rights (including conversion or preemptive rights) or agreements for the purchase or acquisition from
the Company of any shares of its capital stock. The Company has reserved One Million Three Hundred Eighty Thousand (1,380,000) shares of its Common Stock for issuance under the Option Plan. 
 (e) Voting of Shares. Other than the Voting Agreement dated February 22, 2005, which will be amended and restated in
connection with the Closing, the Company is not a party or subject to any agreement or understanding and, to the Company’s knowledge, there is no agreement or understanding between any persons and/or entities which affects or relates to the
voting or giving of written consents with respect to any security or by a director of the Company. 
 (f) Market Stand-Off
/ Right of First Refusal. To the Company’s best knowledge, all outstanding securities of the Company, including, without limitation, all outstanding shares of the capital stock of the Company, all shares of the capital stock of the Company
issuable upon the conversion or exercise of all convertible or exercisable securities and all other securities that the Company is obligated to issue, are subject to (i) a one hundred eighty (180) day “market stand-off”
restriction upon an initial public offering of the Company’s securities pursuant to a registration statement filed with the Securities and Exchange 

  

 2 

 
Commission (“SEC”) pursuant to the Act and (ii) a right of first refusal in favor of the Company with respect to any transfer of
such securities. 
 2.3 Subsidiaries. The Company does not presently own or control, directly or indirectly, any
interest in any other corporation, association, or other business entity. The Company is not a participant in any joint venture, partnership, or similar arrangement. 
 2.4 Authorization. All corporate action on the part of the Company, its officers, directors and stockholders necessary for the
authorization, execution and delivery of this Agreement, the Amended and Restated Investors’ Rights Agreement in the form attached as Exhibit C (the “Investors’ Rights Agreement”), the Right of First Refusal
and Co-Sale Agreement in the form attached as Exhibit D (the “Co-Sale Agreement”) and the Amended and Restated Voting Agreement in the form attached as Exhibit E (the “Voting Agreement”
and collectively with the Investors’ Rights Agreement and Co-Sale Agreement, the “Related Agreements”) the performance of all obligations of the Company hereunder and thereunder, and the authorization, sale and issuance
of the Series A Preferred Stock being sold hereunder and the Common Stock issuable upon conversion of the Series A Preferred Stock has been taken or will be taken prior to the Closing. This Agreement and the Related Agreements constitute valid and
legally binding obligations of the Company, enforceable in accordance with their respective terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies, and (iii) to the extent the indemnification provisions contained
in the Related Agreements may be limited by applicable federal or state securities laws. 
 2.5 Valid Issuance of Preferred
and Common Stock. The Series A Preferred Stock that is being purchased by Investor hereunder, when issued, sold and delivered in accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued,
fully paid and nonassessable and will be free of restrictions on transfer, other than restrictions on transfer (i) under this Agreement and the Related Agreements, (ii) under applicable state and federal securities laws and
(iii) otherwise imposed as a result of actions taken by Investor. The Common Stock issuable upon conversion of the Series A Preferred Stock purchased under this Agreement has been duly and validly reserved for issuance and, upon issuance in
accordance with the terms of the Restated Certificate, will be duly and validly issued, fully paid and nonassessable and will be free of restrictions on transfer, other than restrictions on transfer (i) under this Agreement and the Related
Agreements, (ii) under applicable state and federal securities laws and (iii) otherwise imposed as a result of actions taken by Investor. 
 2.6 Governmental Consents. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority on the
part of the Company is required in connection with the consummation of the transactions contemplated by this Agreement, except for such consents, approvals, orders, authorizations, registrations, qualifications, designations, declarations or filings
which are not required to be obtained prior to the Closing and such filings as are required pursuant to applicable federal and state securities laws and blue sky laws, which filings will be effected within the required statutory period. 

 

 3 

 2.7 Offering. Subject in part to the truth and accuracy of Investor’s
representations set forth in Section 3 of this Agreement, the offer, sale and issuance of the Series A Preferred Stock as contemplated by this Agreement are exempt from the registration requirements of the Securities Act of 1933, as
amended (the “Act”), and the qualification or registration requirements of applicable state blue sky laws, as such registration requirements and laws currently exist. 
 2.8 Litigation. There is no action, suit, proceeding or investigation pending, or to the Company’s knowledge, currently
threatened against the Company that questions the validity of this Agreement or the Related Agreements, or the right of the Company to enter into such agreements or to consummate the transactions contemplated hereby, or that might result, either
individually or in the aggregate, in any material adverse changes in the business, assets or condition of the Company, financially or otherwise, or any change in the current equity ownership of the Company. The Company is not a party or subject to
the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is no action, suit, proceeding or investigation by the Company currently pending or that the Company intends to initiate.

 2.9 Proprietary Information Agreements. Each employee of the Company has executed a Proprietary Information and
Inventions Agreement in substantially the form provided to Investor. The Company is not aware that any such employee is in violation thereof. 
 2.10 Patents and Trademarks. To its knowledge (but without having conducted any special investigation or search), the Company possesses all patents, patent rights, trademarks, trademark rights, service marks,
service mark rights, trade names, trade name rights, copyrights, trade secrets, licenses, information and other proprietary rights and processes (collectively, the “Intellectual Property”) necessary for its business, as now
conducted and as presently proposed to be conducted, without any conflict with or infringement of the valid rights of others, except for Intellectual Property that the Company does not now possess, but that the Company reasonably believes can be
acquired on commercially reasonable terms. The Company has not received any notice of infringement upon or conflict with the asserted rights of others with respect to Intellectual Property. To the Company’s knowledge, all of the issued patents
to which the Company has an exclusive license or right to use are valid and enforceable. 
 2.11 Compliance with Other
Instruments. The Company is not in violation of any material provision of its Restated Certificate or Bylaws nor, to its knowledge, of any instrument, judgment, order, writ, decree or contract, statute, rule or regulation to which the Company is
subject and a violation of which would have a material adverse effect on the condition, financial or otherwise, or operations of the Company. The execution, delivery and performance of this Agreement and the Related Agreements, and the consummation
of the transactions contemplated hereby and thereby will not result in any such violation, or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default under any such provision or an event that
results in the creation of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, impairment, forfeiture or nonrenewal of any material permit, license, authorization or approval applicable to the Company, its
business or operations or any of its assets or properties. 
  

 4 

 2.12 Agreements; Action 
 (a) Except for agreements explicitly contemplated hereby and documents entered into in connection with the founding of the Company, there
are no agreements or understandings between the Company and any of its officers, directors, affiliates or any affiliate thereof. 
 (b) There are no agreements, understandings, instruments, contracts, judgments, orders, writs or decrees to which the Company is a party or by which it is bound that may involve (i) obligations (contingent or otherwise) of, or payments
to the Company, in excess of $10,000, other than obligations of, or payments to, the Company arising from purchase or sale agreements entered into in the ordinary course of business, or (ii) provisions materially restricting the development,
manufacture or distribution of the Company’s products or services. 
 (c) The Company has not (i) declared or paid
any dividends or authorized or made any distribution upon or with respect to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or any other liabilities individually in excess of $10,000 or, in the case
of indebtedness and/or liabilities individually less than $10,000, in excess of $25,000 in the aggregate, (iii) made any loans or advances to any person, other than ordinary advances for travel expenses, or (iv) sold, exchanged or
otherwise disposed of any of its assets or rights. 
 (d) For the purposes of subsections (b) and (c) above, all
indebtedness, liabilities, agreements, understandings, instruments and contracts involving the same person or entity (including persons or entities the Company has reason to believe are affiliated therewith) shall be aggregated for the purpose of
meeting the individual minimum dollar amounts of such subsections. 
 2.13 Related-Party Transactions. No employee,
officer or director of the Company or member of his or her immediate family is indebted to the Company, nor is the Company indebted (or committed to make loans or extend or guarantee credit) to any of them. To the best of the Company’s
knowledge, other than in Investor or in any of Investor’s subsidiaries, none of such persons has any direct or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which the Company has a business
relationship, or any firm or corporation that competes with the Company, except that employees, officers or directors of the Company and members of their immediate families may own stock in publicly traded companies that may compete with the
Company. No member of the immediate family of any officer or director of the Company is directly or indirectly interested in any material contract with the Company. 
 2.14 No Undisclosed Liabilities. Except as set forth in the consolidated financial statements of Arrowhead Research Corporation at
December 31, 2005 and for the three months then ended, the Company does not have any liabilities (whether accrued, absolute, unliquidated, contingent or otherwise, whether or not known to the Company, whether due or to become due and regardless
of when asserted) arising out of transactions entered into at or prior to the Closing, or any action or inaction at or prior to the Closing or any state of facts existing at or 

  

 5 

 
prior to the Closing other than (i) liabilities and obligations that have arisen after December 31, 2005 in the ordinary course of business (none
of which is material and none of which is a liability resulting from breach of contract, breach of warranty, tort, infringement, claim or lawsuit), and (ii) obligations under contracts and commitments incurred in the ordinary course of business
that would not be required to be reflected in financial statements prepared in accordance with generally accepted accounting principles. The Company is not a guarantor or indemnitor of any indebtedness of any other person, firm or corporation.

 2.15 Permits. The Company has all franchises, permits, licenses and any similar authority necessary for the conduct
of its business as now being conducted by it, the lack of which could materially and adversely affect the business, properties or financial condition of the Company, and the Company believes it can obtain, without undue burden or expense, any
similar authority for the conduct of its business as proposed to be conducted. The Company is not in default in any material respect under any of such franchises, permits, licenses or other similar authority. 
 2.16 Environmental and Safety Laws. To its knowledge, the Company is not in violation of any applicable statute, law or regulation
relating to the environment or occupational health and safety, and to its knowledge, no material expenditures are or will be required in order to comply with any such existing statute, law or regulation. 
 2.17 Disclosure. The Company has fully provided Investor with all the information that such Investor has requested for deciding
whether to purchase the Series A Preferred Stock. Neither this Agreement (including all the exhibits and schedules hereto) nor any other statements or certificates made or delivered in connection herewith contains any untrue statement of a material
fact or omits to state a material fact necessary to make the statements herein or therein not misleading in light of the circumstances under which they were made. 
 2.18 Registration Rights. Except as provided in the Investors’ Rights Agreement, the Company has not granted or agreed to
grant any registration rights, including piggyback rights, to any person or entity. 
 2.19 Corporate Documents; Minute
Books. Except for amendments necessary to satisfy representations and warranties or conditions contained herein, the Restated Certificate and Bylaws of the Company are in the form previously provided to special counsel for Investor. The minute
books of the Company provided to Investor contain a complete summary of all meetings or actions of directors and stockholders since the time of incorporation and reflect all transactions referred to in such minutes accurately in all material
respects. 
 2.20 Title to Property and Assets. The property and assets the Company owns are owned by the Company free
and clear of all mortgages, liens, loans and encumbrances, except (i) for statutory liens for the payment of current taxes that are not yet delinquent, and (ii) for liens, encumbrances and security interests that arise in the ordinary
course of business and minor defects in title, none of which, individually or in the aggregate, materially impair the Company’s ownership or use of such property or assets. With respect to the property and assets it leases, the Company is in
material compliance with such leases and, to its knowledge, holds a valid leasehold interest free of any liens, claims or encumbrances, subject to clauses (i)-(ii). 
  

 6 

 2.21 Labor Agreements and Actions. The Company is not bound by or subject to any
contract, commitment or arrangement with any labor union, and no labor union has requested or, to the Company’s knowledge, has sought to represent any of the employees, representatives or agents of the Company. There is no strike or other labor
dispute involving the Company pending, or to the Company’s knowledge, threatened, that could have a material adverse effect on the assets, properties, financial condition, operating results or business of the Company, nor is the Company aware
of any labor organization activity involving its employees. The Company is not aware that any officer or key employee, or that any group of key employees, intends to terminate their employment with the Company, nor does the Company have a present
intention to terminate the employment of any of the foregoing. The employment of each officer and employee of the Company is terminable at the will of the Company. The Company is not a party to or bound by any currently effective employment
contract, deferred compensation agreement, bonus plan, incentive plan, profit sharing plan, retirement agreement or other employee compensation agreement. To its knowledge, the Company has complied in all material respects with all applicable state
and federal equal employment opportunity and other laws related to employment. 
 3. Representations and Warranties of Investor.
Investor hereby represents, warrants and covenants that: 
 3.1 Authorization. Such Investor has full power and
authority to enter into this Agreement and the Related Agreements, and each such agreement constitutes its valid and legally binding obligation, enforceable in accordance with its terms except (i) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other
equitable remedies, and (iii) to the extent the indemnification provisions contained in the Related Agreements may be limited by applicable federal or state securities laws. 
 3.2 Purchase Entirely for Own Account. This Agreement is made with such Investor in reliance upon such Investor’s
representation to the Company, which by such Investor’s execution of this Agreement, such Investor hereby confirms that the Series A Preferred Stock to be received by such Investor and the Common Stock issuable upon conversion thereof
(collectively, the “Securities”) will be acquired for investment for such Investor’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that such Investor
has no present intention of selling, granting any participation in or otherwise distributing the same. By executing this Agreement, such Investor further represents that such Investor does not have any contract, undertaking, agreement or arrangement
with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Securities. 
 3.3 Disclosure of Information. Such Investor believes it has received all the information it considers necessary or appropriate for deciding whether to purchase the Series A Preferred Stock. Such Investor
further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Series A Preferred Stock and the business, properties, prospects and financial
condition of the Company. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 2 of this Agreement or the right of Investor to rely thereon. 
  

 7 

 3.4 Investment Experience. Such Investor is an investor in securities of companies
in the development stage and acknowledges that it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks
of the investment in the Series A Preferred Stock. If other than an individual, such Investor also represents it has not been organized for the purpose of acquiring the Series A Preferred Stock. 
 3.5 Accredited Investor. Such Investor is an “accredited investor” within the meaning of SEC Rule 501 of Regulation D, as
presently in effect. 
 3.6 Restricted Securities. Such Investor understands that the Securities it is purchasing are
characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such
Securities may be resold without registration under the Act only in certain limited circumstances. In the absence of an effective registration statement covering the Securities or an available exemption from registration under the Act, the Series A
Preferred Stock (and any Common Stock issued on conversion thereof) must be held indefinitely. 
 3.7 Legends. It is
understood that the certificates evidencing the Securities may bear one or all of the following legends: 
 (a) “These
securities have not been registered under the Securities Act of 1933, as amended. They may not be sold, offered for sale, pledged or hypothecated in the absence of a registration statement in effect with respect to the securities under such Act or
an opinion of counsel satisfactory to the Company that such registration is not required or unless sold pursuant to Rule 144 of such Act.” 
 (b) Any legend required by applicable laws. 
 4. Conditions of Investor’s Obligations at
Closing. The obligations of Investor under Section 1.1(b) of this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions: 
 4.1 Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall be
true on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the date of such Closing. 
 4.2 Performance. The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before
the Closing. 
  

 8 

 4.3 Compliance Certificate. The President of the Company shall deliver to Investor
at the Closing a certificate stating that the conditions specified in Sections 4.1 and 4.2 have been fulfilled. 
 4.4 Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the
Securities in the Closing pursuant to this Agreement shall be duly obtained and effective as of the Closing, other than such authorizations, approvals or permits or other filings which may be timely made after the Closing. 
 4.5 Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing
and all documents incident thereto shall be reasonably satisfactory in form and substance to the Investor, and it shall have received all such counterpart original and certified or other copies of such documents as it may reasonably request.

 4.6 Restated Certificate. The Restated Certificate of the Company shall have been filed with the Secretary of State
of the State of Delaware and shall continue to be in full force and effect as of the Closing and shall provide that the Board of Directors of the Company shall consist of three (3) persons. 
 4.7 Secretary’s Certificate. Investor shall have received from the Company’s Secretary a certificate having attached
thereto (i) the Company’s Certificate of Incorporation as in effect at the time of the Closing, (ii) the Company’s Bylaws as in effect at the time of the Closing, (iii) resolutions approved by the Board of Directors
authorizing the transactions contemplated hereby, and (iv) resolutions approved by the Company’s stockholders authorizing the filing of the Restated Certificate. 
 4.8 Investors’ Rights Agreement. The Company and Investor shall have entered into the Investors’ Rights Agreement.

 4.9 Co-Sale Agreement. Mark E. Davis, John Rossi, John G. Petrovich, Jeremy Heidel, Patricia Hess, Matthew Vincent,
Mark E. Davis and Mary P. Davis Living Trust dated September 20, 1995, and John G. Petrovich and Rebecca J. Petrovich Revocable Trust dated August 31, 2000 (each, a “Founder” and collectively, the
“Founders”), the Company and Investor shall each have entered into the Co-Sale Agreement. 
 4.10
Voting Agreement. The Founders, Investor and the Company shall have entered into the Voting Agreement. 
 4.11
Agreement to Provide Additional Capital. The Company and Investor shall have entered into the Agreement to Provide Additional Capital attached hereto as Exhibit F (the “Additional Capital Agreement”).

 4.12 Common Stock Transfer Agreement – Form A. The Company, Investor and certain of the holders of the
Company’s Common Stock shall have entered into the Common Stock Transfer Agreement – Form A attached hereto as Exhibit G (the “Form A Transfer Agreement”). 
  

 9 

 4.13 Common Stock Transfer Agreement – Form B. The Company, Investor and
certain of the holders of the Company’s Common Stock shall have entered into the Common Stock Transfer Agreement – Form B attached hereto as Exhibit H (the “Form B Transfer Agreement”). 
 5. Conditions of the Company’s Obligations. The obligations of the Company to Investor under this Agreement in connection with the Closing
are subject to the fulfillment on or before the Closing of each of the following conditions: 
 5.1 Representations and
Warranties. The representations and warranties of Investor contained in Section 3 shall be true on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing.

 5.2 Payment of Purchase Price. Investor shall have delivered to the Company the purchase price specified in
Section 1.1(b) on or prior to the Closing. 
 5.3 Qualifications. All authorizations, approvals or permits,
if any, of any governmental authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Securities in the Closing pursuant to this Agreement shall be duly obtained and
effective as of the Closing, other than such authorizations, approvals or permits or other filings which may be timely made after the Closing. 
 5.4 Investors’ Rights Agreement. The Company and Investor shall have entered into the Investors’ Rights Agreement. 
 5.5 Co-Sale Agreements. The Founders, Investor and the Company shall have entered into the Co-Sale Agreement. 
 5.6 Voting Agreements. The Founders, Investor and the Company shall have entered into the Voting Agreement. 
 5.7 Additional Capital Agreement. The Company and Investor shall have entered into the Additional Capital Agreement. 
 5.8 Form A Transfer Agreement. The Company, Investor and certain of the holders of the Company’s Common Stock shall have
entered into the Form A Transfer Agreement. 
 5.9 Form B Transfer Agreement. The Company, Investor and certain of the
holders of the Company’s Common Stock shall have entered into the Form B Transfer Agreement. 
 6. Miscellaneous. 
 6.1 Survival. The warranties, representations and covenants of the Company and Investor contained in or made pursuant to this
Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of Investor or the Company. 
  

 10 

 6.2 Successors and Assigns. Except as otherwise provided herein, the terms and
conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any Securities). Nothing in this Agreement, express or implied, is intended to confer upon
any party, other than the parties hereto or their respective successors and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 6.3 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to
agreements among California residents entered into and to be performed entirely within California. 
 6.4 Titles and
Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
 6.5 Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon
personal delivery to the party to be notified, (ii) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day; (iii) five days after having been sent by
registered or certified mail, return receipt requested, postage prepaid; or (iv) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall
be sent to the address as set forth on the signature page hereof or at such other address as such party may designate by ten days’ advance written notice to the other parties hereto. 
 6.6 Finder’s Fee. Each party represents that it neither is nor will be obligated for any finders’ fee or commission in
connection with this transaction. Investor agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finders’ fee (and the costs and expenses of defending against such
liability or asserted liability) for which such Investor or any of its officers, partners, employees or representatives is responsible. The Company agrees to indemnify and hold harmless Investor from any liability for any commission or compensation
in the nature of a finders’ fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 
 6.7 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be
waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders of a majority of the Common Stock that is issuable or issued upon conversion of the Series
A Preferred Stock sold pursuant to this Agreement. Any amendment or waiver effected in accordance with this Section 6.7 shall be binding upon each holder of any securities purchased under this Agreement at the time outstanding (including
securities into which such securities are convertible), each future holder of all such securities and the Company. 
 6.8
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement 

  

 11 

 
and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.

 6.9 Aggregation of Stock. All shares of the Series A Preferred Stock or Common Stock issued upon conversion thereof
held or acquired by affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
 6.10 Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties and no
party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically set forth herein or therein. 
 6.11 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. 
 [SIGNATURE PAGE FOLLOWS] 
  

 12 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

  

			
	 COMPANY:
  
 CALANDO PHARMACEUTICALS INC.
 a Delaware corporation

		
	 By:
	 	 /s/ JOHN G. PETROVICH

		 	 John G. Petrovich
 Chief Executive Officer

		
	 Address:
	 	 1701 Flower Avenue, Suite #100
 Duarte, CA 91010
 Fax No. (626) 305-9094

	
	 INVESTOR:
  
 ARROWHEAD RESEARCH CORPORATION
 a Delaware corporation

		
	 By:
	 	 /s/ LEON EKCHIAN

		 	 Leon Ekchian
 President

		
	 Address:
	 	 201 South Lake Avenue, Suite 703
 Pasadena, CA 91101
 Fax No. (626) 792-5554

 [SIGNATURE PAGE TO SERIES A PREFERRED STOCK PURCHASE AGREEMENT] 

 SCHEDULE A 
 SCHEDULE OF EXCEPTIONS 
 The following are the exceptions of Calando Pharmaceuticals Inc. (the
“Company”) to the representations and warranties as set forth in that certain Series A Preferred Stock Purchase Agreement (the “Agreement”) dated as of March 31, 2006. The section numbers in this
Schedule of Exceptions correspond to section numbers in the Agreement. Disclosure of any matters in this Schedule of Exceptions does not constitute an admission that such matter is necessarily required to be disclosed in order for any representation
or warranty in the Agreement to be true and correct to the extent required in the Agreement. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Agreement. 
 Section 2.12(b) 
 License Agreement with Benitec Australia, Ltd. dated as of June 17, 2005. 
 Section 2.12(c) 
 License Agreement with Benitec Australia, Ltd. dated as of June 17, 2005.Agreement to Provide Additional Capital

 Exhibit 10.2 
 AGREEMENT TO PROVIDE ADDITIONAL CAPITAL 
 THIS AGREEMENT TO PROVIDE ADDITIONAL CAPITAL (this
“Agreement”) is made and entered into as of March 31, 2006, by and between ARROWHEAD RESEARCH CORPORATION, a Delaware corporation (“Arrowhead”), and
CALANDO PHARMACEUTICALS INC., a Delaware corporation (the “Company”). 
 A.
Concurrent with the execution and delivery hereof, Arrowhead has entered into that certain Series A Preferred Stock Purchase Agreement of even date herewith (the “Purchase Agreement”), pursuant to which, among other things, Arrowhead has
agreed to purchase 5,000,000 shares of Series A Preferred Stock of the Company (the “Preferred Stock”). 
 B. The Purchase
Agreement has been entered into in contemplation of and in consideration of this Agreement, whereby Arrowhead agrees to contribute $7,000,000 of additional capital to the Company on the terms and conditions set forth herein, provided the Company
meets certain milestones set forth herein. 
 C. This Agreement is being executed and delivered by the parties hereto as contemplated by the
Purchase Agreement. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements set forth below,
the parties hereto agree as follows: 
 1. Commitment to Provide Additional Capital. Arrowhead agrees to provide up to $7,000,000 of
additional capital to the Company, on the following terms and subject to the following conditions: 
 (a) Attached hereto as
Appendix I is a schedule setting forth specified events, the occurrence of which will require future contributions of capital to be made (the “Milestones”). The date upon which each such Milestone shall have been reached is
hereinafter referred to as a “Milestone Date.” 
 (b) Within ten (10) business days following each Milestone
Date, the Company shall deliver to Arrowhead a certificate of the Chief Executive Officer of the Company setting forth, in reasonable detail, sufficient information for Arrowhead to evaluate whether the Company has achieved the specific Milestone to
be achieved by the Milestone Date in question. 
 (c) Arrowhead will have a period of thirty (30) business days following
receipt of the certificate specified in subparagraph 1(b) to evaluate the information provided to Arrowhead by the Company in the certificate. In the event that Arrowhead determines, to its reasonable satisfaction, that the Milestone in question was
achieved by the Company, Arrowhead shall, within such 30-day period, provide to the Company, in cash, by corporate check(s) or wire transfer, the amount of additional capital set forth on Appendix I opposite the Milestone in question.

  

 - 1 - 

 (d) Any and all amounts provided by Arrowhead to the Company pursuant to this Agreement
shall be deemed contributions to the capital of the Company by Arrowhead, as an existing holder of capital stock of the Company. It is understood and agreed that no capital stock or other security of the Company shall be issued to Arrowhead in
consideration or on account of any additional capital provided by Arrowhead to the Company pursuant to the provisions of this Agreement, and that none of such funds shall be considered a loan by Arrowhead to the Company, or otherwise be repayable by
the Company to Arrowhead. 
 2. Failure of Arrowhead to Make a Required Contribution. In the event that Arrowhead fails to provide, on
a timely basis, any amount of additional funding that Arrowhead is obligated to provide pursuant to the provisions of paragraph 1 above (the “Adjustment Event”), then appropriate adjustments will be made to the Preferred Stock pursuant to
the terms of the Company’s Certificate of Incorporation then in effect (the “Certificate”). In the event Arrowhead previously converted all or a portion of its Preferred Stock into Common Stock prior to such Adjustment Event, then, as
provided in this paragraph 2 below, Arrowhead will be required to surrender a portion of its shares of Common Stock to the Company to the extent it no longer holds enough Preferred Stock to provide for the necessary adjustments set forth in the
Certificate. If Arrowhead shall have converted a portion, but not all, of its Preferred Stock into Common Stock prior to an Adjustment Event and, after making the adjustments in the Certificate as a result of the Adjustment Event, the shares of
Preferred Stock held by Arrowhead would convert into a negative number of shares of Common Stock (the “Negative Conversion Shares”), then Arrowhead shall surrender to the Company that number of shares of Common Stock equal to the Negative
Conversion Shares. In the event Arrowhead shall have converted all of its Preferred Stock into Common Stock prior to such Adjustment Event (and therefore the conversion adjustment cannot be calculated), then Arrowhead shall surrender that number of
shares of Common Stock equal to (A) the number of shares of Common Stock issued upon conversion of its Preferred Stock, multiplied by (B) the amount of the additional funding Arrowhead failed to provide in connection with the Adjustment
Event, divided by (C) $10,000,000. The Company shall not have any additional rights or remedies in connection with Arrowhead’s failure to make a contribution as required by this Agreement. 
 3. Optional Contribution. In the event the Company does not achieve one or more of the milestones, Arrowhead may, in its sole discretion,
contribute all or a portion of the $7,000,000 of additional capital to the Company. In addition, nothing herein shall prevent the Company and Arrowhead from agreeing to a future financing transaction on other terms. 
 4. Miscellaneous. 
 (a) Subject to the terms and conditions of this Agreement, each of the parties hereto shall use its best efforts to take, or cause to be taken, all action, and to do, or cause to be done, all things necessary, proper or advisable under
applicable laws, rules and regulations to consummate and make effective the transactions contemplated by this Agreement. 
 (b) This Agreement shall be binding upon and inure to the benefit of the parties hereto, the heirs, personal representatives, successors and permitted assigns of each of the parties hereto, but shall not confer, expressly or by implication,
any rights or remedies upon any 

  

 - 2 - 

 
other party. Neither this Agreement nor any of the rights, interests or obligations of either party hereunder may be assigned without the prior written
consent of the other party. 
 (c) This Agreement shall be governed by and construed in accordance with the General
Corporation Law of the State of Delaware as to matters within the scope thereof, without regard to its principles of conflicts of laws. 
 (d) To the extent any Common Stock of the Company is issued to Arrowhead as a result of a conversion of the shares of Preferred Stock of the Company, the certificates evidencing such securities may bear legends deemed
appropriate acknowledging the terms of this Agreement. 
 (e) All notices, requests or demands and other communications
hereunder must be in writing and shall be deemed to have been duly made if personally delivered or mailed, postage prepaid, to the parties at their respective addresses set forth on the signature page hereof. Any party hereto may change its address
by written notice to the other party given in accordance with this subsection 3(e). 
 (f) This Agreement, together with the
exhibits attached hereto, contains the entire agreement between the parties and supersedes all prior agreements, understandings and writings between the parties with respect to the subject matter hereof and thereof. Each party hereto acknowledges
that no representations, inducements, promises or agreements, oral or otherwise, have been made by any party, or anyone acting with authority on behalf of any party, which are not embodied herein or in an exhibit hereto, and that no other agreement,
statement or promise may be relied upon or shall be valid or binding. Neither this Agreement nor any term hereof may be changed, waived, discharged or terminated orally. This Agreement may be amended or any term hereof may be changed, waived,
discharged or terminated only by an agreement in writing signed by each of the parties hereto. 
 (g) The captions and
headings used herein are for convenience only and shall not be construed as a part of this Agreement. 
 (h) In the event of
any litigation between the parties hereto, the non-prevailing party shall pay the reasonable expenses, including the attorneys’ fees, of the prevailing party in connection therewith. 
 (i) This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which taken together shall
constitute but one and the same document. 
 [SIGNATURE PAGE FOLLOWS] 
  

 - 3 - 

 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement as of the day and
year first above written. 
  

			
	 COMPANY:
  
 CALANDO PHARMACEUTICALS INC.
 a Delaware corporation

		
	 By:
	 	 /s/ JOHN G. PETROVICH

		 	 John G. Petrovich
 Chief Executive Officer

		
	 Address:
	 	 1710 Flower Avenue, Suite #100
 Duarte, CA 91010
 Fax No. (626) 305-9094

	
	 ARROWHEAD:
  
 ARROWHEAD RESEARCH CORPORATION
 a Delaware corporation

		
	 By:
	 	 /s/ LEON EKCHIAN

		 	 Leon Ekchian
 President

		
	 Address:
	 	 201 South Lake Avenue, Suite 703
 Pasadena, CA 91101
 Fax No. (626) 792-5554

 [SIGNATURE PAGE TO AGREEMENT TO PROVIDE ADDITIONAL CAPITAL] 

 APPENDIX I 
 MILESTONE S 
  

							
	  	  	 Description
	  	Capital to be
Contributed	 
	Milestone 1	  	The commencement of IND-enabling toxicity studies for the first internally developed RNAi therapeutic.	  	$	1,000,000.00	 
			
	Milestone 2	  	The filing of the first Investigational New Drug application with the FDA for the first internally developed RNAi therapeutic.	  	$	3,000,000.00	 
			
	Milestone 3	  	Following the occurrence of Milestone 1, the first to occur of: (i) submission of documents to FDA to request approval to commence Phase II clinical trials for an internally developed RNAi
therapeutic; and (ii) the filing of a second Investigational New Drug application with the FDA (whether for an internally developed therapeutic or through a collaboration).	  	$	3,000,000.00	*

  

	*	If Milestone 3 has been satisfied and less than six months has passed since the date upon which Milestone 2 shall have been satisfied, then the contribution of capital associated
with Milestone 3 shall be made on the six month anniversary of the date upon which Milestone 2 shall have been satisfied.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}]]